NANTES, France, January 03, 2023--OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023.
NANTES, France, December 22, 2022--OSE Immuno Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in a Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas
NANTES, France, December 16, 2022--OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the Second Tranche of the Financing Granted by the European Investment Bank